Literature DB >> 12643140

Medical management of obesity: a clinical imperative?

William G Haynes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12643140     DOI： 10.1007/s11892-003-0043-8

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  10 in total

1.  Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.

Authors:  S B Heymsfield; K R Segal; J Hauptman; C P Lucas; M N Boldrin; A Rissanen; J P Wilding; L Sjöström
Journal:  Arch Intern Med       Date:  2000-05-08

2.  The spread of the obesity epidemic in the United States, 1991-1998.

Authors:  A H Mokdad; M K Serdula; W H Dietz; B A Bowman; J S Marks; J P Koplan
Journal:  JAMA       Date:  1999-10-27       Impact factor: 56.272

3.  The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

Authors:  A Fontbonne; M A Charles; I Juhan-Vague; J M Bard; P André; F Isnard; J M Cohen; P Grandmottet; P Vague; M E Safar; E Eschwège
Journal:  Diabetes Care       Date:  1996-09       Impact factor: 19.112

4.  Body weight and mortality among women.

Authors:  J E Manson; W C Willett; M J Stampfer; G A Colditz; D J Hunter; S E Hankinson; C H Hennekens; F E Speizer
Journal:  N Engl J Med       Date:  1995-09-14       Impact factor: 91.245

5.  Beneficial effects of metformin in normoglycemic morbidly obese adolescents.

Authors:  J P Kay; R Alemzadeh; G Langley; L D'Angelo; P Smith; S Holshouser
Journal:  Metabolism       Date:  2001-12       Impact factor: 8.694

6.  Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.

Authors:  K Fujioka; T B Seaton; E Rowe; C A Jelinek; P Raskin; H E Lebovitz; S P Weinstein
Journal:  Diabetes Obes Metab       Date:  2000-06       Impact factor: 6.577

7.  Long-term weight loss with sibutramine: a randomized controlled trial.

Authors:  A Wirth; J Krause
Journal:  JAMA       Date:  2001-09-19       Impact factor: 56.272

8.  Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

Authors:  P A Hollander; S C Elbein; I B Hirsch; D Kelley; J McGill; T Taylor; S R Weiss; S E Crockett; R A Kaplan; J Comstock; C P Lucas; P A Lodewick; W Canovatchel; J Chung; J Hauptman
Journal:  Diabetes Care       Date:  1998-08       Impact factor: 19.112

9.  Body weight change, all-cause mortality, and cause-specific mortality in the Multiple Risk Factor Intervention Trial.

Authors:  S N Blair; J Shaten; K Brownell; G Collins; L Lissner
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391

10.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

Authors:  L Sjöström; A Rissanen; T Andersen; M Boldrin; A Golay; H P Koppeschaar; M Krempf
Journal:  Lancet       Date:  1998-07-18       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.